1. Home
  2. PRPL vs KALA Comparison

PRPL vs KALA Comparison

Compare PRPL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

SELL

Current Price

$2.27

Market Cap

13.9M

ML Signal

SELL

Logo KALA BIO Inc.

KALA

KALA BIO Inc.

HOLD

Current Price

$0.19

Market Cap

13.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRPL
KALA
Founded
2010
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
13.3M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
PRPL
KALA
Price
$2.27
$0.19
Analyst Decision
Buy
Analyst Count
3
0
Target Price
★ $20.63
N/A
AVG Volume (30 Days)
44.1K
★ 439.8K
Earning Date
11-03-2026
11-18-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 152.75
67.39
EPS
N/A
★ N/A
Revenue
★ $468,725,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.50
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.28
$0.07
52 Week High
$10.00
$191.00

Technical Indicators

Market Signals
Indicator
PRPL
KALA
Relative Strength Index (RSI) 40.77 22.47
Support Level $0.36 $0.07
Resistance Level $10.00 $0.61
Average True Range (ATR) 0.16 0.05
MACD 0.09 -0.01
Stochastic Oscillator 58.49 19.23

Price Performance

Historical Comparison
PRPL
KALA

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About KALA KALA BIO Inc.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.

Share on Social Networks: